Journal of Acute Care

Register      Login

VOLUME 2 , ISSUE 2 ( May-August, 2023 ) > List of Articles

CASE REPORT

Fever with Thrombocytopenia—Look beyond Infection: A Case Report

Pooja C Patil, Aishwarya T Kulkarni, Pradeep M Venkategowda, Anand R Sutar

Keywords : Case report, Fever, Promyelocytic leukemia, Thrombocytopenia, Tropical infection

Citation Information : Patil PC, Kulkarni AT, Venkategowda PM, Sutar AR. Fever with Thrombocytopenia—Look beyond Infection: A Case Report. 2023; 2 (2):72-73.

DOI: 10.5005/jp-journals-10089-0071

License: CC BY-NC 4.0

Published Online: 30-10-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Introduction: Patients having fever with thrombocytopenia [febrile thrombocytopenia (FT)] is a common observation in the intensive care unit (ICU). The majority of the cases of FT are infective in origin, and rarely, FT is due to a noninfectious cause. Case Description: This is a case of a 33-year-old male who presented with complaints of fever, myalgia, and loose stools. His routine blood investigation showed thrombocytopenia but was negative for tropical infection tests. The peripheral blood smear had blast cells. Bone marrow aspiration showed hypercellular marrow with blasts of occasional Auer rods. Flow cytometry revealed polymyelocytic (PML)/retinoic acid receptor alpha (RARA) fusion-M3 type of acute myeloid leukemia (AML). This patient was diagnosed as having acute promyelocytic leukemia (APML) and treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Discussion: Febrile thrombocytopenia is one of the common causes of intensive care unit (ICU) admission. It narrows the differential diagnosis among patients admitted to the hospital. Tropical infections/sepsis are the major causes of FT. Hematological malignancies account for <1–2% of FT. Conclusion: This case highlights a rare cause of FT (due to APML). High suspicion of hematological malignancies in patients having FT and early initiation of treatment can reduce morbidity and mortality.


HTML PDF Share
  1. Radhika BV, Sooraj CS, Vasantha K. A study of febrile thrombocytopenia. Int J Contemp Med Res 2019;8(6):121–125. DOI: 10.21276/ijcmr.2019.6.9.20
  2. Yadav V, Singhai A. Study of febrile thrombocytopenia in Malwa region of India. Asian J Med Sci 2017; 8(5):83–86. DOI: 10.3126/ajms.v8i5.17633
  3. Gandhi A, Akholkar P. Clinical and laboratory evaluation of patients with febrile thrombocytopenia. Nat J Med Res 2015;5(1):43–46. https://njmr.in/index.php/file/article/view/34
  4. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;391–399. DOI: 10.1182/asheducation-2008.1.391
  5. Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012;30(32):3921–3923. DOI: 10.1200/JCO.2012.43.0132
  6. Osman AEG, Anderson J, Churpek JE, et al. Treatment of acute promyelocytic leukemia in adults. J Oncol Pract 2018;14(11):649–657. DOI: 10.1200/JOP.18.00328
  7. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 2015;5(4):e304. DOI: 10.1038/bcj.2015.25
  8. Adès L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010;115(9):1690–1696. DOI: 10.1182/blood-2009-07-233387
  9. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369(2):111–121. DOI: 10.1056/NEJMoa1300874
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.